 

Active ingredient: Aprepitant 

 

Form/Route: Capsules/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 
Design: Single-dose, two-way crossover in-vivo 

Strength: 125 mg 

Subjects: Normal healthy males and females, general population 

Additional Comments: 




______________________________________________________________________________ 

 

2. Type of study: Fed 
Design: Single-dose, two-way crossover in-vivo 

Strength: 125 mg 

Subjects: Normal healthy males and females, general population 

Additional comments: 




______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Aprepitant in plasma 

 

Bioequivalence based on (90% CI): Aprepitant 

 

Waiver request of in-vivo testing: 40 mg and 80 mg based on (i) acceptable bioequivalence 
studies on the 125 mg strength, (ii) proportionally similar to the 125 mg strength, and (iii) 
acceptable in vitro dissolution testing. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this 
product at this website. Please conduct comparative dissolution testing on 12 dosage units each 
of all strengths of the test and reference products. Specifications will be determined upon review 
of the application. 

 


